Drug Topics
NOVEMBER 2, 2023
Providers create a disparity themselves by choosing not to treat obesity because stigma has led them to believe that patients with obesity are not sick enough to warrant medical intervention.
Pharmacy Times
NOVEMBER 2, 2023
The increased costs for patients with recurrent hyperkalemia were driven by the increased inpatient medical cost of additional time spent in the hospital following recurrence.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
NOVEMBER 2, 2023
Care home staff play a role in transmission to elderly residents by bringing flu in from their communities, especially in winter. Vaccination can combat this risk, but not all care workers get flu shots.
Pharmacy Times
NOVEMBER 2, 2023
Pharmacy Times will be at the American Society for Nephrology’s (ASN) 2023 Kidney Week Annual Meeting in Philadelphia, Pennsylvania, from November 2 to 5.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
NOVEMBER 2, 2023
A bipartisan group of senators this week introduced a bill that would permanently allow health providers to prescribe buprenorphine , a common medication used to treat opioid addiction, via telehealth. The measure, known as the Telehealth Response for E-prescribing Addiction Therapy Services Act — TREATS, for short — would permanently extend a temporary, Covid-era policy that allowed patients to receive buprenorphine remotely, without an in-person visit.
Pharmacy Times
NOVEMBER 2, 2023
An analysis of the REVOLUTIONIZE II study data showed that there is an unmet need for long-term outpatient treatment of hyperkalemia in patients with CKD.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Pharma
NOVEMBER 2, 2023
The days of booming COVID-19 vaccine sales, which sent Moderna into the ranks of pharma's top companies, have | The company is focusing on scaling back its manufacturing efforts to cope with the lack of COVID-19 vaccine demand.
STAT
NOVEMBER 2, 2023
WASHINGTON — A key Senate panel announced it will consider more policies to regulate pharmacy middlemen and ensure patients aren’t paying more than insurers do for medications. The package crafted by Senate Finance Chair Ron Wyden (D-Ore.) and Mike Crapo (R-Idaho) is slated to be marked up on Nov. 8 , and includes policy on a broad range of health care priorities, including substance abuse and mental health care, and extensions to provider pay.
Pharmacy Times
NOVEMBER 2, 2023
Outside of dialysis and transplantations, implantable artificial kidneys present an additional option for treating kidney disease, according to an expert.
STAT
NOVEMBER 2, 2023
There is a persistent shortage of primary care doctors in the rural United States. Specialists, like OB-GYNs and endocrinologists, are even harder to access. According to the National Rural Health Association, there are only 30 specialists for every 100,000 residents in rural areas, compared to 263 per 100,000 in urban communities. These shortages mean that many patients must routinely drive long distances to see their doctors, or simply go without care.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
NOVEMBER 2, 2023
Panelists at an AMCP Nexus session provided a rundown of the 340B discount program and addressed whether it's actually working to lower out-of-pocket costs for patients.
STAT
NOVEMBER 2, 2023
Kidney transplants are the most common organ transplant procedure in the U.S., with 25,000 taking place in 2022. But for patients who receive new kidneys, the transplant is often followed by severe lifelong challenges, many of which are linked to the immunosuppression drug regimen required after surgery to ensure the body does not reject the new organ.
Fierce Healthcare
NOVEMBER 2, 2023
The Centers for Medicare & Medicaid Services has dropped the final rule to remedy the invalidated 340B-acquired drug payment policy for calendar years 2018 to 2022. | In a statement, American Hospital Association president and CEO Rick Pollack commended the coming repayment to 340B hospitals, but condemned HHS' choice to cut Medicare rates.
STAT
NOVEMBER 2, 2023
WASHINGTON — Medicare officials are moving forward with a plan to claw back money from certain hospitals to try to remedy overpayments struck down by the Supreme Court, they announced Thursday. A federal court ordered the Department of Health and Human Services to compensate hospitals that receive discounted drugs through the 340B program for billions of dollars of underpayments, but the money had already gone out to hospitals that didn’t participate in the program.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Topics
NOVEMBER 2, 2023
Findings from the study highlight potential unmet needs had by patients with mild psoriasis seeking treatment.
STAT
NOVEMBER 2, 2023
Once the domain of aging TV stars, hawking health products from vitamins to diabetes supplies to a geriatric demographic, A-list celebrity endorsements of health care products are positively trendy. Migraine sufferer Lady Gaga has a deal with Nurtec ODT , a prescription drug that treats migraines from pharma company Pfizer. “This Is Us” actor Mandy Moore is contracted by Incyte to promote Opzelura , an eczema treatment.
Fierce Pharma
NOVEMBER 2, 2023
The third quarter marked a momentous one for Sarepta Therapeutics, bringing the long-anticipated launch of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys. | Even before a potential label expansion, the gene therapy Elevidys has raked in around $69 million since its launch. Earlier this week, the company said that a pivotal trial on the medicine failed to reach its primary endpoint.
STAT
NOVEMBER 2, 2023
Over the past five years, two unique federal efforts have collected the health records of millions of Americans. They’ve assembled billions of clinical observations, medication logs, lab results, and more with the goal of supercharging public health research. Now, their dramatically different approaches to data sharing are coming together to put citizens’ real-world health information to work.
Fierce Healthcare
NOVEMBER 2, 2023
When the Affordable Care Act was passed, some feared its changes could lead many employers to drop health coverage altogether. | When the Affordable Care Act was passed, some feared its changes could lead many employers to drop health coverage altogether.
Fierce Pharma
NOVEMBER 2, 2023
Supply problems for Eli Lilly’s diabetes med Mounjaro were no secret. But strong demand continues to push sales of the GLP-1/GIP agonist to new highs ahead of an FDA decision on weight loss. | As strong demand continues to push Mounjaro sales to new highs, Eli Lilly CEO David Ricks said the company is "not done with" manufacturing expansions.
Fierce Healthcare
NOVEMBER 2, 2023
Hospitals’ financials dipped in September as volumes dipped “across the board” and labor expenses inched upward, according to Kaufman Hall’s monthly sector report. | Reduced month-over-month volume metrics and a bump in labor expenses chipped at the hospital sector's operating margins, according to the healthcare consulting firm.
STAT
NOVEMBER 2, 2023
Vascular device maker Inari Medical announced plans to buy LimFlow, a company selling a last-line therapy to save legs with blocked blood flow, on Wednesday. Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success. LimFlow recently snagged Food and Drug Administration approval for its surgical system that uses a stent to connect a blocked artery to an open vein, thus allowing blood to flow through and heal injuries.
Fierce Pharma
NOVEMBER 2, 2023
Ever since Novo Nordisk won FDA approval for its GLP-1 weight-loss med Wegovy more than 2 years ago, analysts and investors have been keeping a close eye on the blockbuster drug launch. | Ever since Novo Nordisk won FDA approval for its GLP-1 weight-loss med Wegovy more than 2 years ago, analysts and investors have been keeping a close eye on the blockbuster drug launch.
STAT
NOVEMBER 2, 2023
When is a failure not a failure? Does the FDA have special rules for Sarepta Therapeutics? And how do you say “brash” in French? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Biotech consultant Frank David joins us to explain the wild world of subgroup analyses and how to discern science from spin.
Drug Topics
NOVEMBER 2, 2023
Vaccine manufacturers, including Novavax, are still hard at work updating immunizations against a mutating SARS-CoV-2 virus.
Fierce Pharma
NOVEMBER 2, 2023
In a span of three days, Phathom Pharmaceuticals has scored two green lights from the FDA for its first-in-class heartburn drug Voquezna (vonoprazan). | In a span of three days, Phathom Pharmaceuticals has scored two green lights from the FDA for its first-in-class heartburn drug Voquezna. The first came on Monday when the regulator signed off on Phathom’s reformulation of Voquezna to treat Helicobacter pylori infection.
European Pharmaceutical Review
NOVEMBER 2, 2023
While unsolicited and burdensome, medicine shortages are an obstacle faced by the pharmaceutical industry. In 2023, a combination of factors, including increased demand (particularly for critical medicines), economic inflation, as well as international geopolitical unrest, has led to Europe’s supply chain being acutely affected. Consequently, regulators, trade groups and other organisations have worked to prevent and alleviate medicine shortages in the region.
Fierce Pharma
NOVEMBER 2, 2023
Roche’s surge in sales for its long-acting macular degeneration drug Vabysmo showed that patients in the market are open to switching to another treatment. | After gaining FDA approval for its high-dose Eylea, Regeneron racked up $43 million in sales in the U.S. over the final six weeks of the third quarter for the new formulation. Regeneron and partner Bayer are battling Roche's Vabysmo in the treatment of multiple eye diseases.
Drug Store News
NOVEMBER 2, 2023
Pantene is kicking off its partnership with Tini Stoessel by naming her its newest Healthy Hair Ambassador and also sharing the plans to sponsor her first tour in the United States.
Fierce Healthcare
NOVEMBER 2, 2023
Hospitals are taking their campaign against the Department of Health and Human Services’ (HHS’) “rule for thee but not for me” crackdown on third-party web trackers to the courts. | The hospital lobby said the tools—which are currently in use on the government's own health websites—are needed to better spread health information and increase access.
Pharmacy Times
NOVEMBER 2, 2023
The approval marks the first major innovation in the United States for the treatment of erosive GERD in over 30 years.
STAT
NOVEMBER 2, 2023
Lately, we’ve seen two distinct lines at our hospitals. We would all be healthier if we brought the two lines together. The first line forms every morning before the building opens. Mothers, children, and the disabled clutch passels of documents along the sidewalk. They wait to reauthorize their Medicaid insurance.
Pharmacy Times
NOVEMBER 2, 2023
How patients acquire NSCLC plays a role in health outcomes, with never-smoker patients having genetically different disease than the same disease in smokers.
Drug Store News
NOVEMBER 2, 2023
At NACDS’ Total Store Expo, DSN caught up with iA’s Tom Utech and Bobbi Jamriska about what’s new with the pharmacy automation solutions company.
Expert insights. Personalized for you.
201 
Let's personalize your content